# Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069

> **NCT01100047** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 63 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD5069
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01100047
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100047, "Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01100047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*